Quest for safe muscarinic receptor agonists to tackle disaster prone CNS field steers Karuna to $75M IPO
Less than a year after raising $42 million, banking on the potential of two older drugs as an approach to fight Alzheimer’s and schizophrenia, Boston-based Karuna Pharmaceuticals on Friday laid the groundwork for a $75 million IPO.
The PureTech-backed company is working on the hypothesis that a combination of muscarinic acetylcholine receptor agonist xanomeline — an Eli Lilly castoff — and trospium chloride, an FDA-approved muscarinic receptor antagonist together will make an adept antipsychotic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.